Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
9 drugs in development
By Therapeutic Area
top 1
R&D Momentum
59/100
Pipeline Velocity
34/100
Trial Completion Rate
62/100
Pipeline Concentration
68/100
Pipeline Freshness
46/100
Activity
Last 14 days
Online Adaptive Radiotherapy With a Boost to the Primary Tumor and Clinically Involved Lymph Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer: A Prospective, Randomized Controlled Trial
An Exploratory Clinical Study to Evaluate the Safety, Tolerability and Biodistribution Characteristics of 177 Lu FAP VG11 Injection in Patients With Advanced Solid Tumours
Olanzapine 2.5 mg Versus 5 mg Versus 10 mg in Highly Emetogenic Regimens: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)